Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis

Cancer Science

Volumn 99, Issue 10, 2008, Pages 1977-1983

  Koga, Yoshikatsu ^a,b   Yasunaga, Masahiro ^a   Moriya, Yoshihiro ^c   Akasu, Takayuki ^c   Fujita, Shin ^c   Yamamoto, Seiichiro ^c   Kozu, Takahiro ^d   Baba, Hideo ^b   Matsumura, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CARCINOEMBRYONIC ANTIGEN; MATRILYSIN; MESSENGER RNA; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE 2; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CELL ISOLATION; COLORECTAL CANCER; CONTROLLED STUDY; EARLY DIAGNOSIS; FECES ANALYSIS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR LOCALIZATION; TUMOR VOLUME;

ADULT; AGED; CELL CYCLE PROTEINS; COLONOSCOPY; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DNA; DNA, COMPLEMENTARY; FEASIBILITY STUDIES; FECES; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOMAGNETIC SEPARATION; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 54949121368     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00954.x     Document Type: Article

References (36)

1. World Health Organization (WHO). World Health Report 2004. Available from URL: http://www.who.int/healthinfo/bodgbd2002revised/en/index.html
2. Bosman FT. Prognostic value of pathological characteristics of colorectal cancer. Eur J Cancer 1995; 31A: 1216-21.
3. Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ 1998; 317: 559-65.
4. Winawer S, Fletcher R, Rex D et al. Colorectal cancer screening and surveillance: Clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003; 124: 544-60.
5. Mandel JS, Church TR, Bond JH et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1603-7.
6. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001; 345: 555-60.
7. Sung JJ, Chan FK, Leung WK et al. Screening for colorectal cancer in Chinese: Comparison of fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. Gastroenterology 2003; 124: 608-14.
8. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351: 2704-14.
9. Sidransky D, Tokino T, Hamilton SR et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256: 102-5.
10. Ahlquist DA, Skoletsky JE, Boynton KA et al. Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel. Gastroenterology 2000; 119: 1219-27.
11. Rengucci C, Maiolo P, Saragoni L, Zoli W, Amadori D, Calistri D. Multiple detection of genetic alterations in tumors and stool. Clin Cancer Res 2001; 7: 590-3.
12. Traverso G, Shuber A, Olsson L et al. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002; 359: 403-4.
13. Traverso G, Shuber A, Levin B et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002; 346: 311-20.
14. Itzkowitz SH, Jandorf L, Brand R et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol 2007; 5: 111-7.
15. Zou H, Harrington J, Rego RL, Ahlquist DA. A novel method to capture methylated human DNA from stool: Implications for colorectal cancer screening. Clin Chem 2007; 53: 1646-51.
16. Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003; 49: 1058-65.
17. Zou H, Harrington JJ, Klatt KK, Ahlquist DA. A sensitive method to quantify human long DNA in stool: Relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2006; 15: 1115-19.
18. Hasegawa Y, Takeda S, Ichii S et al. Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA). Oncogene 1995; 10: 1441-5.
19. Guadagni F, Kantor J, Aloe S et al. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers. Cancer Res 2001; 61: 2523-32.
20. Guller U, Zajac P, Schnider A et al. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002; 236: 768-75; discussion 75-6.
21. Schuster R, Max N, Mann B et al. Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers. Int J Cancer 2004; 108: 219-27.
22. Guo J, Xiao B, Jin Z et al. Detection of cytokeratin 20 mRNA in the peripheral blood of patients with colorectal cancer by immunomagnetic bead enrichment and real-time reverse transcriptase-polymeras chain reaction. J Gastroenterol Hepatol 2005; 20: 1279-84.
23. Lloyd JM, McIver CM, Stephenson SA, Hewett PJ, Rieger N, Hardingham JE. Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Clin Cancer Res 2006; 12: 417-23.
24. Oberg AN, Lindmark GE, Israelsson AC, Hammarstrom SG, Hammarstrom ML. Detection of occult tumour cells in lymph nodes of colorectal cancer patients using real-time quantitative RT-PCR for CEA and CK20 mRNAS. Int J Cancer 2004; 111: 101-10.
25. Ohlsson L, Hammarstrom ML, Israelsson A et al. Biomarker selection for detection of occult tumour cells in lymph nodes of colorectal cancer patients using real-time quantitative RT-PCR. Br J Cancer 2006; 95: 218-25.
26. Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology 2004; 127: 422-7.
27. Leung WK, To KF, Man EP et al. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps. Am J Gastroenterol 2007; 102: 1070-6.
28. Yamao T, Matsumura Y, Shimada Y et al. Abnormal expression of CD44 variants in the exfoliated cells in the feces of patients with colorectal cancer. Gastroenterology 1998; 114: 1196-205.
29. Matsushita H, Matsumura Y, Moriya Y et al. A new method for isolating colonocytes from naturally evacuated feces and its clinical application to colorectal cancer diagnosis. Gastroenterology 2005; 129: 1918-27.
30. Sjoblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-74.
31. Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992; 340: 1053-8.
32. Matsumura Y, Hanbury D, Smith J, Tarin D. Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells. Bmj 1994; 308: 619-24.
33. Onouchi S, Matsushita H, Nomura S, Minowa T, Matsumura Y. PCR-based assessment of the recovery rate of exfoliated colonocytes or cancer cells from fecal samples depends on the storage conditions after defecation. J Gastrointestin Liver Dis 2007; 16: 369-72.
34. Regula J, Rupinski M, Kraszewska E et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med 2006; 355: 1863-72.
35. Barclay RL, Vicari JJ, Doughty AS, Johanson JF, Greenlaw RL. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 2006; 355: 2533-41.
36. Shah HA, Paszat LF, Saskin R, Stukel TA, Rabeneck L. Factors associated with incomplete colonoscopy: A population-based study. Gastroenterology 2007; 132: 2297-303.